Citations

Mayo Clinic

Clear

2474 citation(s) found for "Ee, Miller".

Single-cell transcriptomic atlas of frontoinsular cortex reveals molecular correlates of selective neuronal vulnerability in FTD
Breevoort, Arnar , Ivanov, Dimitar, Horan-Portelance, Liam , Nana, Alissa , Vatsavayai, Sarat, Miravet, Alex Tudoras, Wallace, Jenelle L., Ding, Jingwen W., Pereira, Felipe L., Fernhoff, Kristen, Gorno-Tempini, Maria Luisa, Spina, Salvatore, Yokoyama, Jennifer S., Rosen, Howard J., Grinberg, Lea T., Jacobs, Frank M. J., Miller, Bruce L., Seeley, William , Pollen, Alex A , Nana, Alissa L , Breevoort, Arnar , Horan-Portelance, Liam , Vatsavayai, Sarat C. , Tudoras, Àlex, Wallace, Jenelle L. , Ding, Jingwen W, Pereira, Felipe L., Fernhoff, Kristen, Gorno‐Tempini, Maria Luisa , Spina, Salvatore , Yokoyama, Jennifer S. , Rosen, Howard J. , Grinberg, Lea T. , Jacobs, Frank M. J. , Seeley, William W.

No container title available | July 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.13.738307 | PMID 42523377 Get It

Abstract Frontotemporal dementia (FTD) is characterized by selective neuronal vulnerability, yet the features that predispose specific neuron types to degeneration remain unclear. We performed single-nucleus RNA sequencing of frontoinsular cortex, a region affected early in behavioral variant FTD, across individuals with C9orf72 -associated and sporadic FTD-MND spectrum disease. By enriching for large projection neurons, we resolved molecular subtypes of layer 5 extratelencephalic neurons, including von Economo neurons, and identified selective depletion of specific layer 2/3 and layer 5 neuron subtypes, convergent across genotypes. Despite selective neuronal loss, disease-associated transcriptional changes were convergent across excitatory neuron populations, suggesting that they reflect upstream pathophysiology or shared responses to local neurodegeneration. By relating neighborhood-level depletion in disease to gene expression in controls, we found that baseline cellular respiration and ATP synthesis predict neuronal vulnerability in disease. These findings define molecular correlates of selective neuronal vulnerability in FTD and provide a framework linking cell type and state to neurodegeneration.
Comparative Seizure Outcomes of Vagus Nerve Stimulation, Deep Brain Stimulation, and Their Combination in Lennox–Gastaut Syndrome
Kuo, Cheng‐Yen , Singh, Raunak, Sharma, Shelja, Nguyen, Ryan D. , Wong‐Kisiel, Lily C. , Starnes, Keith , Gregg, Nicholas M. , Gompel, Jamie Van, Miller, Kai J., Worrell, Gregory A. , Wong-Kisiel, Lily C. , Van Gompel, Jamie, Lundstrom, Brian Nils , Worrell, Gregory A , Gregg, Nicholas M , Singh, Raunak , Starnes, Donnie Keith , Kuo, Cheng‐Yen , Nguyen, Ryan Toan Dinh , Gompel, Jamie J. Van , Miller, Kai J. , Lundstrom, Brian N.

Annals of Neurology | July 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ana.78308 | PMID 42446202 Get It

Objective Lennox–Gastaut syndrome (LGS) is a severe treatment‐resistant epilepsy. Although vagus nerve stimulation (VNS) and deep brain stimulation (DBS) are established therapies, comparative data and the impact of dual neuromodulation remain limited. We compared seizure outcomes across VNS, DBS, and combined DBS + VNS therapy in LGS. Methods This retrospective cohort study at Mayo Clinic (2005–2024) included LGS patients treated with VNS and/or DBS . Seizure frequency was assessed at 6, 12, and 24 months post‐stimulation. Responder was defined as 50% or more seizure reduction. Results Forty patients were included (42% female, median, 150 seizures/month). Eleven patients underwent sequential VNS followed by DBS and contributed data to 2 treatment epochs, yielding 3 treatment groups: VNS alone (n = 29), DBS alone (n = 12), and DBS + VNS (n = 10). At 24 months, median seizure reduction rate was comparable between VNS (50%; 95% confidence interval [ CI], 44–75%) and the overall DBS cohort (59%, 95% CI, 33–86%) ( p = 0.54). However, a significant difference emerged when comparing the 3 treatment arms ( p = 0.027). Specifically, DBS + VNS therapy yielded significantly greater median reduction rate (81%, 95% CI, 60–99%) than DBS alone (43%, 95% CI, 0–58%) ( p adj = 0.027) or VNS alone (50%, 95% CI, 44.4–75.0%) ( p adj = 0.048). Four patients attained sustained seizure freedom above 1 year at last follow‐up. Interpretation VNS and DBS provide comparable seizure reduction in LGS over a 2‐year follow‐up period. DBS + VNS was associated with further improvements in seizure reduction in this small, retrospective dataset. This possibility warrants further investigation. ANN NEUROL 2026
The conducting airways before and after gender‐affirming hormone therapy in transgender individuals
Kipp, Shalaya , Ramsook, Andrew H. , Miller, Alex J., Bustos, Samyd S., Martinez‐Jorge, Jorys, Welch, Brian T., Ripoll, Juan G., Miller, Alex J. , Joyner, Michael J , Ramsook, Andrew H , Kipp, Shalaya , Bustos, Samyd S. , Martinez‐Jorge, Jorys, Welch, Brian T. , Ripoll, Juan G. , Joyner, Michael J.

Experimental Physiology | July 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1113/ep093927 | PMID 42446094 Get It

Abstract On average, females have smaller airways than males. The largest discrepancy in airway size occurs during puberty, when endogenous sex hormone concentrations diverge between males and females. Transgender individuals often use gender‐affirming hormone therapy (GAHT) to align physical characteristics with gender identity. It is unknown whether GAHT influences airway size (luminal area and length). We evaluated the large conducting airways before starting GAHT and while undergoing years of GAHT. This retrospective within‐subject study included 12 adult transgender individuals who underwent CT scanning before starting GAHT and again after ≥1 year of GAHT. For each transgender individual, we identified two matched cisgender controls (one male and one female) who also underwent two CT scans over a comparable time interval for longitudinal comparison. We used a three‐dimensional reconstruction of CT imaging to measure luminal areas. Within‐subject changes in airway size between scans were assessed using Student's paired t ‐tests in transgender individuals undergoing feminizing hormone therapy. Variance between scans was assessed using Levene's test. Pre‐scans occurred an average of 2.0 ± 3.1 years before beginning GAHT. Transgender persons were on GAHT for an average of 3.3 ± 1.7 years (range, 1.0 – 6.7 years) at their second scan. We found no significant differences in airway luminal cross‐sectional areas for transgender persons on feminizing hormone therapy. The variance in airway size change between scans was not statistically different between transgender individuals and control subjects. Our findings suggest that the size of large conducting airways might remain unchanged after a period (>1 year) on GAHT.
International Expert Consensus on the Diagnosis and Clinical Management of Primary Fetal Pleural Effusion
Abiad, May , Javinani, Ali, Lopez, Maria C., Mossayebi, Matthew H., Mieghem, Tim Van, Russo, Francesca, Ruano, Rodrigo , Britto, I.S. , Miller, Russell, Yinon, Yoav, Cincotta, Robert, Perrone, Erin E. , Sago, Haruhiko , Haak, Monique C., Sans, Mar Bennasar, Gonzalez, Gerardo Sepulveda, Chmait, Ramen H., Habli, Mounira, Sun, Raphael C., Chaveeva, Petya, Espinoza, Jimmy, Schenone, Mauro , Sun, Lu‐Ming, Nassr, Ahmed A., Moon‐Grady, Anita, Shamshirsaz, Alireza A., Krispin, Eyal, Araujo Júnior, Edward , Britto, Ingrid Schwach Werneck , Perrone, Erin E , Sago, Haruhiko , Khalil, Asma , Meller, Cesar , Mustafa, Hiba J , Schenone, Mauro H , Papanna, Ramesha , Ruano, Rodrigo , Abiad, May , Javinani, Ali , Mossayebi, Matthew H. , Van Mieghem, Tim , Russo, Francesca Maria , Miller, Russell , Yinon, Yoav , Cincotta, Robert , Haak, Monique C. , Sans, Maria del Mar Bennasar, Gonzalez, G. Sepulveda, Chmait, Ramen H. , Habli, Mounira A. , Chaveeva, Petya , Espinoza, Jimmy , Nassr, Ahmed A. , Moon‐Grady, Anita J. , Shamshirsaz, Alireza A. , Krispin, Eyal

Prenatal Diagnosis | July 14, 2026 | Volume: 46 | Issue: 9 | Pages: 1312-1322

10.1002/pd.70221 | PMID 42444393 Get It

ABSTRACT Objective(s) Fetal pleural effusion is a rare condition that may significantly impact fetal and neonatal outcomes. Currently, no universal standardized approach exists for diagnosing and managing primary fetal pleural effusions. This study aimed to develop structured, expert‐based clinical guidelines for the diagnosis, monitoring, management, and follow‐up care of primary fetal pleural effusion. Methods A Delphi method was employed to achieve consensus among an international panel of experts in fetal medicine. Experts were selected based on their clinical expertise, affiliations, and relevant publications. A three‐round anonymous electronic survey was sent to the full panel. In the initial two rounds, participants rated each statement on a Likert scale (1–5) and provided suggestions for modifications. Statements with a median score of five and no suggested changes were accepted as consensus. Statements with a median score below four were rejected. Statements scoring a median of four were revised according to suggestions and reconsidered in the subsequent round. In the final round, participants indicated their agreement or disagreement with the remaining statements. Consensus was defined as agreement from more than 70% of participants with no suggestions for further changes. Results A total of 101 expert clinicians accepted the invitation and completed the first round with 73 (72%) completing all three rounds. Consensus statements were achieved on aspects of diagnosis, monitoring, intervention, post‐intervention management, and delivery. Key recommendations concerning the diagnosis of primary fetal pleural effusion include the use of ultrasound as the primary modality for identifying fetal pleural effusion and excluding secondary causes through detailed genetic, infectious, and metabolic evaluations. Management strategies emphasized thoracoamniotic shunting as the preferred intervention in hydropic fetuses with primary pleural effusion. Experts reached consensus that shunt placement could be offered as early as 16 weeks. No consensus was reached for isolated effusion without hydrops, as management was considered case‐dependent. The importance of ultrasonographic monitoring of fetal status at least weekly post‐intervention was strongly endorsed. Conclusion(s) The Delphi method facilitated the development of a consensus‐based protocol for diagnosing and managing primary fetal pleural effusion. These standardized guidelines are intended to enhance clinical practice across various settings, improve perinatal outcomes, and serve as a foundation for future research for this high‐risk fetal condition.
Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy
Miner, A, Zetterberg, Henrik, Blennow, Kaj, Groh, Jenna R., Singh, Alpana, Dieckhoff, Kari, Tripodis, Yorghos, Adler, Charles H., Balcer, Laura J. , Bernick, C L, Peskind, Elaine, Asken, Breton M., Tanner, Jeremy A., Rabinovici, Gil D., Banks, Sarah J., Barr, William B., Wethe, Jennifer V., Cantu, Robert C., Dodick, David W., Mez, Jesse, Palmisano, J, Martin, Brett, Stein, Thor D., McKee, Ann C., Cummings, Jeffrey L., Shenton, Martha E., Reiman, E Bieto, Rc, Stern, Ashton, Nicholas J., Alosco, Michael L., Chen, Kewei, Protas, Hillary, Su, Yi, Boker, Connie, Au, Rhoda, Farrer, Lindsay, Helm, Robert, Kowall, Neil, Mercier, Gustavo, Otis, James, Weller, Jason, Bragg, Tahlia, Simkin, Irene, Trujillo-Rodriguez, Diana, Amerongen, Suzan van , Andino, Alondra, Conneely, Shannon, Diamond, Courtney, Fagle, Tessa, Haller, Olivia, Hunt, Tennyson, Gullotti, Nicole, Kossow, Bailey, Kugelmass, Carrie, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen, Nanna, Mary, DiPopolo, Marty, Platt, Taylor, Rice, Fiona, Sestak, Madison, McClean, Michael, Annis, Douglas, Chaisson, Christine, Dixon, Diane, Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Lu, Jun, Ojo, E O, Pine, Brittany, Ramachandran, Janani, Baucom, Zachary, Tuz‐Zahra, Fatima , Yhang, Eukyung , Bouix, Sylvain, Fitzsimmons, Jennifer, Lin, Alexander P., Koerte, Inga K., Pasternak, Ofer, Arciniega, Hector , Billah, Tashrif , Bonke, Elena, Breedlove, Katherine M. , Carrington, Holly, Coello, Eduardo , Coleman, Michael J., John, Omar , Jung, Leonard, Liao, Huijun, Loy, Maria, Rizzoni, Elizabeth, Schulz, V. D., Silva, Annelise, Vessey, Brynn, Wiegand, Tim L.T, Miller, Jason, Ritter, Aaron , Sabbagh, Marwan, Cruz, Raelynn de la, Durant, Jan, Golceker, Morgan, Harmon, Nicolette, Kaylegian, Jaeson, Long, Rachelle, Nance, Christine, Sandoval, Priscilla, Staples, Miranda, Clark, Emma F., Serrano, Andrew, Geda, Yonas, Duffy, Amy, Falk, Bryce, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Bellgowan, Patrick, GOLDBERG, JUDITH, Joseph, Binu , Kirov, Ivan, Lui, Yvonne, Marmar, Charles, Wisniewski, T R, Al-Kharafi, Alhassan, George, Allan, Hasanaj, Lisena, Martin, Sammie, Riley, Edward, Runge, William, Serrano, Liliana , Iliff, Jeffrey, Li, Gail, Janssen, D, Meabon, James, Piantino, Juan, Schindler, Abigail, Thomas, Ronald, Colasurdo, Elizabeth , Shofer, Jane, Marcus, Daniel S., Gurney, Jenny , Greenwald, Richard, Johnson, Keith A., Singh, Alpana , Singh, Alpana , Miner, Annalise E., Zetterberg, Henrik , Blennow, Kaj , Groh, Jenna R. , Singh, Alpana, Tripodis, Yorghos , Adler, Charles H. , Bernick, Charles , Peskind, Elaine R. , Asken, Breton M. , Rabinovici, Gil D. , Banks, Sarah J. , Barr, William , Wethe, Jennifer V. , Cantu, Robert C. , Dodick, David W. , Mez, Jesse , Stein, Thor D. , McKee, Ann C. , Cummings, Jeffrey L. , Shenton, Martha E. , Reiman, Eric M. , Ashton, Nicholas J. , Alosco, Michael L. , Protas, Hillary , Au, Rhoda, Weller, Jason , Trujillo‐Rodriguez, Diana , Fagle, Tessa, Mariani, Megan, McLaughlin, Kathleen , Pulukuri, Surya Vamsi , Sestak, Madison, McClean, Michael D , Annis, Douglas, Finney, Carolyn, Lu, Jun, Pine, Brittany, Ramachandran, Janani , Baucom, Zachary, Bouix, Sylvain , Koerte, Inga K , Pasternak, Ofer , Bonke, Elena M. , Carrington, Holly , Coleman, Michael J. , Liao, Huijun, Schulz, Vivian, Wiegand, Tim L. T. , II, Robert W. Turner , Marek, Kenneth , Geda, Yonas E. , Howard, Marci, Montague, Michelle, Babcock, Debra, Bellgowan, Patrick S.F. , Kirov, Ivan, George, Allan, Meabon, James S. , Piantino, Juan , Thomas, Ronald G. , Colasurdo, Elizabeth A. , Shofer, Jane, Marcus, Daniel S., Johnson, Keith A.

JAMA Network Open | July 13, 2026 | Volume: 9 | Issue: 7 | Pages: e2622966

10.1001/jamanetworkopen.2026.22966 | PMID 42440317 Get It

Importance In vivo biomarkers for detecting neuropathologies from repetitive head impacts (RHI), including chronic traumatic encephalopathy (CTE), are needed. Objective To evaluate the utility of plasma phosphorylated tau 217 (p-tau217), assess its performance as a beta-amyloid (Aβ) biomarker in participants with RHI exposure at risk for CTE, and explore concordance with CTE neuropathology in a postmortem subsample. Design, Setting, and Participants This longitudinal, multicenter, case-control study used data from the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of CTE (DIAGNOSE CTE) Research Project, collected from September 2016 to October 2023. Participants were former American football players (case participants) and asymptomatic men unexposed to RHI (control participants). A subsample had available neuropathologic data. Exposures RHI, traumatic encephalopathy syndrome (TES) diagnoses, and levels of CTE certainty. Main Outcomes and Measures Plasma p-tau217 (classified as positive [≥0.63 pg/mL], intermediate [0.40-0.62 pg/mL], and negative [<0.40 pg/mL]), Aβ–positron emission tomography (PET; 18 F-florbetapir; with Aβ-positive defined as a standardized uptake value ratio [SUVR] ≥1.10), and tau-PET ( 18 F-flortaucipir). TES diagnoses were assigned by multidisciplinary consensus conference. Analyses of postmortem brains controlled for age, race, and APOE ε4 status. Results Among 231 participants (mean [SD] age, 57.75 [8.25] years), 177 were former football players (117 professional and 60 college) and 54 were unexposed participants. Former football players had higher baseline mean (SD) p-tau217 concentrations than unexposed participants (0.35 [0.26] pg/mL vs 0.27 [0.14] pg/mL; P = .008), although this was driven by a higher proportion of Aβ-PET–positive participants among former players. Plasma p-tau217 increased over time across the sample (B = 0.207 [95% CI, 0.117-0.298]; P < .001), with no significant time × exposure group interactions. Among football players, p-tau217 showed no time × group interactions with TES diagnosis, TES-CTE certainty, or RHI metrics. Higher p-tau217 concentration correlated with higher global Aβ-PET SUVR (B = 0.058 [95% CI, 0.053-3.501; P = .01), with a few discordant cases (5 participants were p-tau217–negative and Aβ-PET–positive; 7 participants were p-tau217–positive and Aβ-PET–negative). P-tau217 had similar areas under the curve for projecting Aβ-PET positivity as cerebrospinal fluid (CSF) p-tau181/Aβ42 and CSF Aβ40/42 measures (p-tau217: AUC, 0.88 [95% CI, 0.80-0.96]; CSF p-tau181/Aβ42: AUC, 0.89 [95% CI, 0.79-1.00]; CSF Aβ40/42: AUC, 0.85 [95% CI, 0.72-0.98]). Among 9 brain donors, 6 had CTE (stages II-IV; none with Alzheimer disease). Seven had negative or intermediate p-tau217, concordant with Aβ-PET. Two p-tau217 outliers with stage III CTE had normal concentrations upon additional testing. Conclusions and Relevance The findings of this study suggest that plasma p-tau217 concentration is unlikely to be useful for the detection of CTE, but it does show utility for ruling out Aβ pathology in participants at risk for CTE.
Shared lipidome and proteome signatures of frontotemporal lobar degeneration and Alzheimer’s disease
Ambaw, Yohannes, Nana, Alissa, Li, Zhuoning , Singh, S , Monetti, Mara , Miller, Bruce L, Spina, Salvatore, Seeley, William W, Farese, Robert, Ambaw, Yohannes Abere , Nana, Alissa , Spina, Salvatore , Grinberg, Lea T. , Seeley, William W. , Walther, Tobias C. , Farese, Robert V.

No container title available | July 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.11.737778 | PMID 42465421 Get It

Abstract Frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease (AD) differ in their clinical features and genetic etiologies but share progressive cognitive decline. Emerging evidence implicates lipid dysregulation in neurodegeneration, but its extent across FTLD subtypes and how it compares to AD are unclear. Here, we performed integrated lipidomic and proteomic analyses of matched frontal (disease-vulnerable) and occipital (relatively spared) post-mortem cortices from individuals with genetic and sporadic FTLD-TDP, FTLD-tau (Pick’s disease, PiD), AD, and controls. FTLD and AD exhibited convergent lipid alterations, including reduced levels of cardiolipins and phosphatidylethanolamines, alongside increased gangliosides, diacylglycerols, cholesterol esters, acylcarnitines, and coenzyme Q, with generally greater changes in FTLD frontal cortex. FTLD displayed additional alterations, including reductions in bis(monoacylglycerol)phosphate, ceramides, phosphatidylserines, phosphatidylinositols, and sulfatides. These lipid changes were accompanied by proteomic alterations involving lysosomal proteins, phospholipases, phospholipid remodeling enzymes, and fatty acid oxidation pathways. Although lipidomic and proteomic signatures were broadly shared across FTLD subtypes, GRN associated FTLD-TDP and PiD showed the most extensive alterations. Triglycerides were selectively reduced in PiD in association with decreased DGAT1 expression, whereas cholesterol esters were elevated across all subtypes except C9orf72 associated FTLD-TDP. These findings identify shared disruptions in lipid homeostasis and lysosomal lipid metabolism across FTLD and AD, highlighting convergent metabolic pathways underlying neurodegeneration.
Attention reshapes the information dynamics of thalamic and cortical prediction-error learning
Äijälä, Juho , Jensen, Michael A. , Miller, Kai J. , Hermes, Dora , Blenkmann, Alejandro O. , Ince, Robin A. A. , Bekinschtein, Tristán , Vinck, Martin , Garagnani, Max , Jensen, Michael A , Vinck, Martin , Hermes, Dora , Canales‐Johnson, Andrés

No container title available | July 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.10.737794 Get It

Abstract Prediction errors (PEs) drive perceptual learning by updating internal models of the sensory environment, yet it remains unclear how attention reshapes their representation across distributed thalamocortical circuits. Using intracranial stereoelectroencephalography (sEEG) from 17 patients performing a roving auditory oddball task under attended and unattended conditions, we quantified PE encoding using mutual information and co-information to capture redundant and synergistic PE representations. Attention modulated PE encoding in both the thalamus and the temporal cortex, but with distinct informational dynamics. Thalamic encoding showed a stable reduction of PE information during distraction, consistent with state-dependent thalamocortical gating. In contrast, the temporal cortex expressed two opposing learning trajectories during attended listening that converged once attention was diverted, revealing distinct cortical learning regimes rather than a uniform attentional effect. Attention further reorganized the informational content of cortical PE representations by altering the balance between redundant and synergistic information. A biologically constrained neural network showed that attention-dependent changes in inhibition and long-range connectivity reproduced these dynamics through Hebbian learning. Together, these findings suggest that attention regulates predictive learning not simply by changing the strength of PE responses, but by reshaping how distributed thalamocortical circuits represent and integrate sensory evidence over time.
A Low-Cost, Open-Source Wireless Platform for Real-Time Tremor Monitoring in Parkinson's Disease
Heydari, Hossein, Arslan, Ebubekir E., Okkabaz, Jhan L., Branco, Luciano R. F., Hall, Matthew J., Swamy, Chandra Prakash , Klassen, Bryan T., Ali, R Zomorodi, Miller, Kai, Viswanathan, Ashwin, Ince, Nuri F., Ali, Rushna P, Ali, Rushna , Arslan, Ebubekir Enes , Branco, Luciano, Klassen, Bryan T. , Miller, Kai J. , Viswanathan, Ashwin , Ince, Nuri F.

2025 12th International IEEE/EMBS Conference on Neural Engineering (NER) | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 587-591

10.1109/ner61569.2025.11589100 | PMID 42621937 Get It

Integrating Spatial-Temporal Channel Reliability with AI for Robust High-Frequency Oscillation Detection in Intracranial EEG*
Besheli, Behrang Fazli , Ayyoubi, Amir Hossein , Swamy, Chandra Prakash , Mohan, Bobby, Miller, Kai J., Parker, Jonathan J., Worrell, Gregory A., Ince, Nuri F., Miller, Kai J., Worrell, Gregory A. , Ince, Nuri F.

2025 12th International IEEE/EMBS Conference on Neural Engineering (NER) | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 511-516

10.1109/ner61569.2025.11588994 | PMID 42677172 Get It

Data-Driven Hyperparameter Tuning of High-Frequency Oscillation Detection for Seizure-Onset Zone Localization
Hrtonová, Valentina , Kolajová, Martina , Besheli, Behrang Fazli , Ayyoubi, Amir Hossein , Okkabaz, Jhan L., Swamy, Chandra Prakash , Miller, Kai J., Worrell, Gregory A., Ince, Nuri F., Worrell, Gregory A. , Ince, Nuri F.

2025 12th International IEEE/EMBS Conference on Neural Engineering (NER) | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 64-69

10.1109/ner61569.2025.11588923 | PMID 42626223 Get It